Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Trident Lifeline
Quarter-by-quarter operating performance
Financials of Trident Lifeline
Annual income statement trend
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales + | 22 | 32 | 45 | 87 | 129 |
| Expenses + | 19 | 25 | 36 | 72 | 101 |
| Operating Profit | 3 | 6 | 8 | 15 | 28 |
| OPM % | 12% | 20% | 18% | 17% | 22% |
| Other Income + | 1 | 1 | 2 | 8 | 9 |
| Interest | 0 | 0 | 1 | 4 | 4 |
| Depreciation | 0 | 0 | 1 | 5 | 6 |
| Profit before tax | 3 | 7 | 9 | 14 | 27 |
| Tax % | -32% | 8% | 32% | 23% | 29% |
| Net Profit + | 4 | 6 | 6 | 10 | 19 |
| EPS in Rs | 4.94 | 5.24 | 5.51 | 10.22 | 15.96 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Financials of Trident Lifeline
Capital structure and asset base
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 8 | 12 | 12 | 12 | 12 |
| Reserves | -3 | 34 | 41 | 53 | 88 |
| Borrowings + | 2 | 8 | 18 | 54 | 73 |
| Other Liabilities + | 7 | 9 | 16 | 37 | 63 |
| Total Liabilities | 14 | 63 | 87 | 156 | 237 |
| Fixed Assets + | 1 | 3 | 21 | 44 | 61 |
| CWIP | 0 | 5 | 4 | 2 | 18 |
| Investments | 0 | 3 | 4 | 11 | 8 |
| Other Assets + | 12 | 51 | 58 | 99 | 150 |
| Total Assets | 14 | 63 | 87 | 156 | 237 |
Financials of Trident Lifeline
Operating, investing and financing cash movement
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from Operating Activity + | -0 | -19 | 2 | -10 | 5 |
| Cash from Investing Activity + | -0 | -10 | -20 | -14 | -37 |
| Cash from Financing Activity + | 1 | 42 | 11 | 20 | 34 |
| Net Cash Flow | 0 | 14 | -7 | -4 | 2 |
| Free Cash Flow | -1 | -26 | -16 | -21 | -29 |
| CFO/OP | -8% | -294% | 56% | -38% | 45% |
Financials of Trident Lifeline
Working capital efficiency and return ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 83 | 139 | 110 | 116 | 208 |
| Inventory Days | 95 | 129 | 156 | 226 | 174 |
| Days Payable | 134 | 87 | 94 | 119 | 183 |
| Cash Conversion Cycle | 44 | 182 | 173 | 224 | 199 |
| Working Capital Days | 49 | 275 | 205 | 144 | 134 |
| ROCE % | 23% | 15% | 18% | 21% |
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…